Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.

Tablets orally twice a day to maintain protocol specific target blood levels

Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.

Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.